-
Mashup Score: 4Overview of the 2024 EAS Congress - 11 month(s) ago
We asked Professor Kausik Ray, President of the European Atherosclerosis Society about 2024 EAS Congress and the Society, as well as the Joint Sessions and the Anitschkow Lecture.
Source: medicaldigest.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 2Late Breaking Clinical Trial on ACC - 12 month(s) ago
Professor Athena Poppas shared his insights on the Late Breaking Clinical Trial sessions: – Effect Of Edetate Disodium Based Chelation Infusions On Cardiovascular Events In Post-MI Patients With Diabetes: The TACT2 Trial – Percutaneous Transvalvular Micro-axial Flow Pump In Infarct Related Cardiogenic Shock: Results Of The Danger-shock Trial – A Selective Aldose Reductase Inhibitor (at-001) For The Treatment Of Diabetic Cardiomyopathy: Primary Results Of The Phase 3 Randomized Controlled Arise-hf Study
Source: medicaldigest.orgCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 5Highlights of the ASH 2023 Congress - 1 year(s) ago
Professor Mikkael Sekeres summarizes the most important highlights that presented at the 65th American Society of Hematology Annual Meeting.
Source: medicaldigest.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
Professor Borja Ibanez co-chaired of the new 2023 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndromes. This is the first time an “ACS” guideline has been published encompassing the full spectrum of the syndrome including unstable angina, non ST- elevation myocardial infarction and ST elevation myocardial infarction. You can access the document on the ESC website by clicking here.
Source: medicaldigest.orgCategories: Cardiologists1, Latest HeadlinesTweet
-
Mashup Score: 0
Prof. Matteo Lambertini explains the highlights of the 2023 ESMO Breast Cancer Conference. – There are more insights of the toxicity of the new ACDs, paticullary for trastuzumab deruxtecan. Updated data on the DESTINY (DESTINY-Breast04, 02) trials in the terms of toxicities. – CAPItello-291, capivasertib to fulvestrant improves progression-free survival for key subgroups of patients with…
Source: medicaldigest.orgCategories: Hem/Oncs, Latest HeadlinesTweet
RT @MedicalDigestCR: 📽️ Prof. Kausik Ray's, EAS President summary of the #EASCongress2024. -> https://t.co/yDe1oCAsbp @ProfKausikRay @EASCo…